08 January 2019
Visiongain has launched a new pharma report Magnetic Resonance Imaging Systems Market Report : High-Field MRI, Ultra-High Field MRI, Low-Field MRI.
Rapid expansions in the applications of MRI and an increased medical awareness of MRI systems as a diagnostic tool have triggered strong growth in this market in recent years. As this trend continues, and new applications are discovered (coupled with continued product innovation), the market will continue to achieve strong revenue growth. The future of the MRI devices market look promising, as more innovative devices are in the R&D pipeline and eventually enters the market. In the recent years, there have been progressive improvements in the safety, comfort, convince and efficacy of MRI devices, yet there is potential for more innovation. With steady progression of the industry, MRI equipment will gain popularity among healthcare providers, with that market expanding worldwide and the devices developed to address a wider range of medical conditions. As MRI markets in developed countries mature, emerging national markets will continue to drive the growth of MRI sales, as a result of increased healthcare spending.
The lead analyst of the report commented "Opportunities in the market include the development and increased preference towards ultra-high field systems which are capable of imaging ions and neurotransmitters, ultimately achieving a new level of diagnostic imaging.
There are strong opportunities for market growth in rising countries such as China and India where the density of MRI scanners per million of the population is a major concern. As the global awareness of the benefits of MRI increases, and in response to strong patient demand, government spending in healthcare in these respective countries is expected to increase. This will ultimately provide strong opportunities for market players to direct their focus towards emerging countries, rather than in developed countries, where the MRI market is steadily reaching saturation."
Leading companies featured in the report include Aurora Healthcare US Corp, Bruker Corporation, Canon Medical Systems, Esaote SpA, GE Healthcare, Hitachi, Ltd., Neusoft Medical Systems Co., Ltd., Philips Healthcare, Shenzhen Anke High-tech Co., Ltd., Siemens Healthineers
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.